Please assess the completion status of the following clinical trial:

Trial Title: Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Select Inclusion Criteria:~1. Histological or cytological diagnosis of HCC.~2. The subject has disease that is not amenable to a curative treatment approach.~3. Received prior sorafenib.~4. Progression following at least 1 prior systemic treatment for HCC.~5. Recovery to from toxicities related to any prior treatments.~6. ECOG performance status of 0 or 1.~7. Adequate hematologic and renal function, based upon meeting protocol defined laboratory criteria within 7 days before randomization.~8. Child-Pugh Score of A.~9. Antiviral therapy per local standard of care if active hepatitis B (HBV) infection.~10. Sexually active fertile subjects(male and female)must agree to use medically accepted methods of contraception during the course of the study and for 4 months after the last dose of study treatment.~11. Female subjects of childbearing potential must not be pregnant at screening.~Select Exclusion Criteria:~1. Fibrolamellar carcinoma or mixed hepatocellular cholangiocarcinoma.~2. Receipt of more than 2 prior systemic therapies for advanced HCC.~3. Any type of anticancer agent (including investigational) within 2 weeks before randomization.~4. Radiation therapy within 4 weeks (2 weeks for radiation for bone metastases) or radionuclide treatment within 6 weeks of randomization.~5. Prior cabozantinib treatment.~6. Known brain metastases or cranial epidural disease unless adequately treated with radiotherapy and/or surgery and stable for at least 3 months before randomization.~7. Concomitant anticoagulation, at therapeutic doses, with anticoagulants.~8. Serious illness other than cancer that would preclude safe participation in the study.~9. Subjects with untreated or incompletely treated varices with bleeding or high risk for bleeding.~10. Moderate or severe ascites.~11. Pregnant or lactating females.~12. Diagnosis of another malignancy within 2 years before randomization, except for superficial skin cancers, or localized, low-grade tumors.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cabozantinib (XL184) (Type: EXPERIMENTAL): Cabozantinib (XL184) 60 mg tablet once daily
- Placebo (Type: PLACEBO_COMPARATOR): Oral cabozantinib-matched placebo tablet once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).